prikaz prve stranice dokumenta Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment
  Download
PDF 152.75 KB
Scientific paper - Original scientific paper
Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment
HIV Medicine, 21 (2020), 9; 599-606. https://doi.org/10.1111/hiv.12888
Mocroft, A; Neesgard, B; Zangerle, R; Rieger, A; Castagna, A; Spagnuolo, V; Antinori, A; Lampe, FC; Youle, M; Vehreschild, JJ; Mussini, C; Borghi, V; Begovac, Josip; Duvivier, C; Gunthard, HF; Rauch, A; Tiraboschi, J; Chkhartishvili, N; Bolokadze, N; Wit, F; Wasmuth, JC; De Wit, S; Necsoi, C; Pradier, C; Svedhem, V; Stephan, C; Petoumenos, K; Garges, H; Rogatto, F; Peters, L; Ryom, L More authors...

Cite this document

Mocroft, A., Neesgard, B., Zangerle, R., Rieger, A., Castagna, A., Spagnuolo, V. ... Ryom, L. (2020). Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment. HIV Medicine, 21. (9), 599-606. doi: 10.1111/hiv.12888

Mocroft, A, et al. "Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment." HIV Medicine, vol. 21, no. 9, 2020, pp. 599-606. https://doi.org/10.1111/hiv.12888

Mocroft, A, B Neesgard, R Zangerle, A Rieger, A Castagna, V Spagnuolo, A Antinori, et al. "Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment." HIV Medicine 21, no. 9 (2020): 599-606. https://doi.org/10.1111/hiv.12888

Mocroft, A., et al. (2020) 'Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment', HIV Medicine, 21(9), pp. 599-606. doi: 10.1111/hiv.12888

Mocroft A, Neesgard B, Zangerle R, Rieger A, Castagna A, Spagnuolo V, and sur.. Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment. HIV Medicine [Internet]. 2020 June 26 [cited 2024 April 12];21(9):599-606. doi: 10.1111/hiv.12888

A. Mocroft, et al., "Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment", HIV Medicine, vol. 21, no. 9, pp. 599-606, June 2020. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:601886. [Accessed: 12 April 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment
AuthorA Mocroft
AuthorB Neesgard
AuthorR Zangerle
AuthorA Rieger
AuthorA Castagna
AuthorV Spagnuolo
AuthorA Antinori
AuthorFC Lampe
AuthorM Youle
AuthorJJ Vehreschild
AuthorC Mussini
AuthorV Borghi
AuthorJosip Begovac
AuthorC Duvivier
AuthorHF Gunthard
AuthorA Rauch
AuthorJ Tiraboschi
AuthorN Chkhartishvili
AuthorN Bolokadze
AuthorF Wit
AuthorJC Wasmuth
AuthorS De Wit
AuthorC Necsoi
AuthorC Pradier
AuthorV Svedhem
AuthorC Stephan
AuthorK Petoumenos
AuthorH Garges
AuthorF Rogatto
AuthorL Peters
AuthorL Ryom
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Infectious Diseases)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Infectology
Abstract (english)
Objectives: Although outcomes of antiretroviral therapy (ART) have been evaluated in randomized controlled trials, experiences from subpopulations defined by age, CD4 count or viral load (VL) in heterogeneous real-world settings are limited. ----- Methods: The study design was an international multicohort collaboration. Logistic regression was used to compare virological and immunological outcomes at 12 ± 3 months after starting ART with an integrase strand transfer inhibitor (INSTI), contemporary nonnucleoside reverse transcriptase inhibitor (NNRTI) or boosted protease inhibitor (PI/b) with two nucleos(t)ides after 1 January 2012. The composite treatment outcome (cTO) defined success as VL < 200 HIV-1 RNA copies/mL with no regimen change and no AIDS/death events. Immunological success was defined as a CD4 count > 750 cells/μL or a 33% increase where the baseline CD4 count was ≥ 500 cells/μL. Poisson regression compared clinical failures (AIDS/death ≥ 14 days after starting ART). Interactions between ART class and age, CD4 count, and VL were determined for each endpoint. ----- Results: Of 5198 ART-naïve persons in the International Cohort Consortium of Infectious Diseases (RESPOND), 45.4% started INSTIs, 26.0% PI/b and 28.7% NNRTIs; 880 (17.4%) were aged > 50 years, 2539 (49.4%) had CD4 counts < 350 cells/μL and 1891 (36.8%) had VL > 100 000 copies/mL. Differences in virological and immunological success and clinical failure among ART classes were similar across age groups (≤ 40, 40-50 and > 50 years), CD4 count categories (≤ 350 vs. > 350 cells/μL) and VL categories at ART initiation (≤ 100 000 vs. > 100 000 copies/mL), with all investigated interactions being nonsignificant (P > 0.05). ----- Conclusions: Differences among ART classes in virological, immunological and clinical outcomes in ART-naïve participants were consistent irrespective of age, immune suppression or VL at ART initiation. While confounding by indication cannot be excluded, this provides reassuring evidence that such subpopulations will equally benefit from contemporary ART.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleHIV Medicine
Numberingvol. 21, no. 9, pp. 599-606
p-ISSN1464-2662
e-ISSN1468-1293
DOIhttps://doi.org/10.1111/hiv.12888
URN:NBNurn:nbn:hr:105:601886
Publication2020-06-26
Document URLhttps://onlinelibrary.wiley.com/doi/10.1111/hiv.12888
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) icon
Created on2021-03-24 08:54:07